Merck ends Cholesterol drug study

Singapore, May 22, 2008: American pharma giant Merck has discontinued ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia... [read full story]